Loading clinical trials...
Loading clinical trials...
A Phase 3, Multi-Center, Randomized, Double-Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)
Conditions
Interventions
NOV03
Placebo
Locations
29
United States
Bausch Site 124
Birmingham, Alabama, United States
Bausch Site 125
Scottsdale, Arizona, United States
Bausch Site 110
Glendale, California, United States
Bausch Site 121
Long Beach, California, United States
Bausch Site 102
Mission Hills, California, United States
Bausch Site 101
Newport Beach, California, United States
Start Date
July 20, 2020
Primary Completion Date
March 12, 2021
Completion Date
March 12, 2021
Last Updated
October 23, 2024
NCT07463950
NCT07396441
NCT06841471
NCT07268599
NCT07503886
NCT06981104
Lead Sponsor
Bausch & Lomb Incorporated
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions